Cytokinetics, Incorporated
US ˙ NasdaqGS ˙ US23282W6057

Introduction

This page provides a comprehensive analysis of the known insider trading history of Andrew Callos. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Andrew Callos has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CYTK / Cytokinetics, Incorporated EVP, Chief Commercial Officer 52,028
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Andrew Callos. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CYTK / Cytokinetics, Incorporated - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CYTK / Cytokinetics, Incorporated. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CYTK / Cytokinetics, Incorporated Insider Trades
Insider Sales CYTK / Cytokinetics, Incorporated - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CYTK / Cytokinetics, Incorporated. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-06-05 CYTK Callos Andrew 8,659 32.0400 8,659 32.0400 277,434 0 32.0800 347 0.12
2025-05-05 CYTK Callos Andrew 4,002 36.6800 4,002 36.6800 146,793
2025-04-07 CYTK Callos Andrew 2,886 35.7800 2,886 35.7800 103,261
2025-03-17 CYTK Callos Andrew 20,900 45.1400 20,900 45.1400 943,426
2025-03-17 CYTK Callos Andrew 2,775 44.3800 2,775 44.3800 123,154
2025-03-14 CYTK Callos Andrew 100 45.0000 100 45.0000 4,500
2025-03-13 CYTK Callos Andrew 26,771 43.6200 26,771 43.6200 1,167,751
2025-03-06 CYTK Callos Andrew 3,341 43.2700 3,341 43.2700 144,565
2025-03-03 CYTK Callos Andrew 1,114 42.8800 1,114 42.8800 47,768

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CYTK / Cytokinetics, Incorporated Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Andrew Callos as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-05 2025-06-05 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -8,659 52,028 -14.27 32.04 -277,434 1,666,977
2025-05-05 2025-05-05 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -4,002 60,687 -6.19 36.68 -146,793 2,225,999
2025-04-07 2025-04-07 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -2,886 64,689 -4.27 35.78 -103,261 2,314,572
2025-03-18 2025-03-14 4 CYTK CYTOKINETICS INC
Common Stock
A - Award 32,687 70,350 86.79
2025-03-17 2025-03-17 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -20,900 37,663 -35.69 45.14 -943,426 1,700,108
2025-03-17 2025-03-17 4 CYTK CYTOKINETICS INC
Common Stock
M - Exercise 20,900 58,563 55.49 23.26 486,134 1,362,175
2025-03-17 2025-03-17 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -2,775 34,888 -7.37 44.38 -123,154 1,548,329
2025-03-14 2025-03-14 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -100 37,663 -0.26 45.00 -4,500 1,694,835
2025-03-14 2025-03-14 4 CYTK CYTOKINETICS INC
Common Stock
M - Exercise 100 37,763 0.27 23.26 2,326 878,367
2025-03-13 2025-03-13 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -26,771 37,663 -41.55 43.62 -1,167,751 1,642,860
2025-03-07 2025-03-06 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -3,341 64,434 -4.93 43.27 -144,565 2,788,059
2025-03-05 2025-03-03 4 CYTK CYTOKINETICS INC
Common Stock
S - Sale -1,114 67,775 -1.62 42.88 -47,768 2,906,192
2024-12-05 2024-12-03 4 CYTK CYTOKINETICS INC
Common Stock
A - Award 3,177 68,889 4.83
2024-12-05 2024-12-03 4 CYTK CYTOKINETICS INC
Common Stock
F - Taxes -1,351 65,712 -2.01 51.51 -69,590 3,384,825
2024-12-05 2024-12-03 4 CYTK CYTOKINETICS INC
Common Stock
A - Award 3,176 67,063 4.97
2024-03-18 2024-03-14 4 CYTK CYTOKINETICS INC
Common Stock
A - Award 16,941 63,887 36.09
2024-03-07 2024-03-06 4 CYTK CYTOKINETICS INC
Common Stock
F - Taxes -5,103 46,946 -9.80 66.88 -341,289 3,139,748
2024-03-07 2024-03-04 4 CYTK CYTOKINETICS INC
Common Stock
F - Taxes -2,202 52,049 -4.06 67.68 -149,031 3,522,676
2023-03-07 2023-03-06 4 CYTK CYTOKINETICS INC
Common Stock
A - Award 30,000 53,683 126.67
2023-03-03 2023-03-02 4 CYTK CYTOKINETICS INC
Common Stock
F - Taxes -2,202 23,683 -8.51 39.60 -87,199 937,847
2023-02-17 2023-02-16 4 CYTK CYTOKINETICS INC
Common Stock
F - Taxes -969 25,885 -3.61 44.13 -42,762 1,142,305
2022-03-03 2022-03-02 4 CYTK CYTOKINETICS INC
Non-Qualified Stock Option (right to buy)
A - Award 31,715 31,715 37.63 1,193,435 1,193,435
2022-03-03 2022-03-02 4 CYTK CYTOKINETICS INC
Incentive Stock Option (right to buy)
A - Award 13,285 13,285 37.63 499,915 499,915
2022-03-03 2022-03-02 4 CYTK CYTOKINETICS INC
Common Stock
A - Award 20,000 26,196 322.79
2022-02-17 2022-02-16 4 CYTK CYTOKINETICS INC
Common Stock
A - Award 3,125 6,196 101.76
2022-02-17 2022-02-16 4 CYTK CYTOKINETICS INC
Common Stock
A - Award 1,919 3,071 166.58
2021-04-05 2021-03-31 4 CYTK CYTOKINETICS INC
Non-Qualified Stock Option (right to buy)
A - Award 150,000 150,000 23.26 3,489,000 3,489,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)